Islam Zobida, Yamamoto Shohei, Mizoue Tetsuya, Oshiro Yusuke, Inamura Natsumi, Nemoto Takeshi, Konishi Maki, Ozeki Mitsuru, Sugiura Wataru, Ohmagari Norio
Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Toyama 1-21-1, Shinjuku-Ku, Tokyo 162-8655, Japan.
Department of Laboratory Testing, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
Vaccines (Basel). 2022 Dec 14;10(12):2142. doi: 10.3390/vaccines10122142.
Increased γ-glutamyl transpeptidase (GGT) levels can deplete plasma glutathione, which in turn impairs immune regulation; however, evidence on GGT levels and post-vaccine immunogenicity is lacking.
To examine the association between GGT and SARS-CoV-2 spike IgG antibodies.
Participants were 1479 medical staff (aged 21 to 75 years) who received a SARS-CoV-2 antibody test after their second vaccine and whose GGT levels were measured before the vaccine rollout. Elevated and highly elevated GGT levels were defined as 51-80 and ≥81 U/L, respectively. Multivariable linear regression was used to calculate the means of SARS-CoV-2 spike IgG.
In a basic model, both elevated and highly elevated GGT levels were associated with significantly lower antibody titers. The ratio of mean (95% CI) was 0.83 (0.72-0.97) and 0.69 (0.57-0.84) for elevated and highly elevated GGT levels, respectively. However, these associations were largely attenuated after additional adjustment for potential confounders. An inverse association between GGT levels and antibody titers was found in women [0.70 (0.51-0.97)], normal-weight adults [0.71 (0.51-0.98)], and non-drinkers [0.73 (0.46-1.14)] but not in men, overweight adults, and alcohol drinkers.
Circulating GGT concentrations were associated with the humoral immune response after COVID-19 vaccination, but this relationship could be ascribed to confounders such as sex, BMI, and alcohol drinking rather than GGT per se.
γ-谷氨酰转肽酶（GGT）水平升高会消耗血浆谷胱甘肽，进而损害免疫调节；然而，关于GGT水平与疫苗接种后免疫原性的证据尚缺乏。
研究GGT与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白IgG抗体之间的关联。
研究对象为1479名医务人员（年龄21至75岁），他们在接种第二剂疫苗后接受了SARS-CoV-2抗体检测，且在疫苗接种前测量了GGT水平。GGT水平升高和高度升高分别定义为51-80 U/L和≥81 U/L。采用多变量线性回归计算SARS-CoV-2刺突蛋白IgG的均值。
在基础模型中，GGT水平升高和高度升高均与抗体滴度显著降低相关。GGT水平升高和高度升高时，均值（95%置信区间）的比值分别为0.83（0.72-0.97）和0.69（0.57-0.84）。然而，在对潜在混杂因素进行进一步调整后，这些关联在很大程度上减弱。在女性[0.70（0.51-0.97）]、正常体重成年人[0.71（0.51-0.98）]和不饮酒者[0.73（0.46-1.14）]中发现GGT水平与抗体滴度呈负相关，而在男性、超重成年人和饮酒者中未发现这种相关性。
循环GGT浓度与2019冠状病毒病（COVID-19）疫苗接种后的体液免疫反应相关，但这种关系可能归因于性别、体重指数和饮酒等混杂因素，而非GGT本身。
